Company News: AstraZeneca

Share this article:
AstraZeneca announced plans to cut 8,000 jobs -- around 12% of its global workforce -- by 2014 as part of a cost-cutting exercise. The firm, which has already eliminated 12,600 jobs in recent years, will lose US market exclusivity on Arimidex and Pulmicort Respules this year and has projected a revenue decline in the mid-single digits for the year. The company will also restructure its R&D function to focus on fewer disease area targets and close some R&D sites.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.